-
Register Now: Step 1 Ultrasound Course on May 17-18
-
Exclusive Member Discount on Cancer Rehabilitation Book
-
Drs. Agarwal and Burkard: In the News, November 28, 2018
-
Just Announced: 2019 Plenary Speakers
-
Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA
-
Meet Your 2019 Board of Governors
-
FDA alerts health care professionals and patients not to use sterile drug products from Pharm D Solutions
-
Implanted Pumps: Safety Communication - Use Caution When Selecting Pain Medicine for Intrathecal Administration
-
Congratulations to Our 25-Year Members
-
Drs. Judelson, Rak, Wenzel: In the News, November 14, 2018
-
December 12: 2019 Quality Payment Program (QPP) Reporting Requirements Webinar
-
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
-
December 5: Virtual Town Hall on 2019 Physician Fee Schedule
-
E/M Reimbursement in 2019: What You Need to Know
-
Introducing WATCHmē® Instructional Videos
-
ALERT: Extortion Scam Targeting DEA Registrants
-
Roche Diagnostics Recalls CoaguChek XS PT Test Strips Due to Inaccurate INR Test Results
-
ALERT: AAPM&R Analyzing Final 2019 Medicare Physician Fee Schedule Released
-
Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)
-
AAPM&R Collaborating with ABPMR and AAP on the Current ACGME's Program Requirements for Pain Medicine